サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1599891

酵素補充療法 (ERT) の世界市場：産業分析・規模・シェア・成長・動向・予測 (2024-2031年)

Enzyme Replacement Therapy Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

出版日
ページ情報
英文 181 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.91円
酵素補充療法 (ERT) の世界市場：産業分析・規模・シェア・成長・動向・予測 (2024-2031年)
出版日: 2024年11月27日
発行: Persistence Market Research
ページ情報: 英文 181 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

主な洞察

  • 酵素補充療法 (ERT) の市場規模 (2024年)：110億米ドル
  • 市場規模の予測 (2031年) ：177億米ドル
  • 世界の市場成長率 (2024～2031年)：CAGR 7.1%

市場促進要因：

世界の酵素補充療法 (ERT) の市場は、ゴーシェ病、ファブリー病、ポンペ病などの希少遺伝性疾患の有病率の上昇、診断率の向上による治療需要の押し上げなどの主な要因によって牽引されます。バイオテクノロジー、特に組換えDNA技術の進歩により、非常に効果的で的を絞った治療法の開発が可能になっています。さらに、財政支援や償還政策による政府の支援が治療へのアクセスを拡大し、教育キャンペーンや患者支援団体による認知度の向上が診断率や治療法の普及を後押ししています。

市場の抑制要因：

酵素補充療法 (ERT) の市場は大きな可能性を示す一方で、注目すべき課題に直面しています。研究、製造、流通に関連する費用を含む高い治療費は、中低所得地域での利用を制限しています。さらに、生物学的に活性な酵素に必要な複雑な製造工程は、厳格な規制遵守を要求するため、商業化が遅れることが多くあります。さらに、一部の患者では副作用として免疫反応が現れるため、慎重なモニタリングと調整が必要となり、より広範な市場導入の妨げとなる可能性があります。

市場機会：

酵素補充療法 (ERT) の市場は、研究の進展や戦略的提携に後押しされ、豊富な機会が示されています。アジア太平洋やラテンアメリカなどの新興市場は、認知度の向上と医療インフラの改善により、大きな成長の可能性を秘めています。ゲノム研究とバイオマーカー分析によって促進される個別化医療の台頭は、有効性を高めるためのオーダーメイドのERTソリューションを可能にしています。製薬会社、研究機関、支援団体間の戦略的パートナーシップは、技術革新を加速し、酵素療法の適用範囲を拡大しています。さらに、経口酵素製剤と遺伝子治療の開発は、従来の静脈内治療に取って代わる可能性のある変革的な変化を示しています。

当レポートでは、世界の酵素補充療法 (ERT) の市場を調査し、市場の定義と概要、市場促進要因・抑制要因、各種動向、市場機会、課題、市場規模(金額・一部数量) の推移・予測、各種区分・地域/主要国別の詳細分析、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の範囲と定義
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
    • 主な動向
  • マクロ経済要因
    • 世界のセクター別展望
    • 世界のGDP成長見通し
    • 世界の医療費支出見通し
  • COVID-19の影響分析
  • 予測要因：関連性と影響

第3章 付加価値の洞察

  • 対象疾患別の採用分析
  • 技術評価
  • 規制状況
  • バリューチェーン分析
  • 主要な取引と合併
  • PESTLE分析
  • ポーターのファイブフォース分析

第4章 価格動向分析

  • 主なハイライト
  • 製品価格に影響を与える主な要因
  • 対象疾患別の価格分析
  • 地域別の価格と製品の好み

第5章 世界の酵素補充療法市場の展望：推移・予測

  • 主なハイライト
    • 市場規模の予測
    • 市場規模・前年比成長率
    • 収益機会
  • 市場規模の分析・予測
  • 世界の酵素補充療法市場の展望：対象疾患別
    • 市場規模の推移
    • 市場規模の予測
  • 市場の魅力分析：対象疾患別
  • 世界の酵素補充療法市場の展望：投与経路別
    • 市場規模の推移
    • 市場規模の予測
  • 市場の魅力分析：投与経路別
  • 世界の酵素補充療法市場の展望：流通チャネル別
    • 市場規模の推移
    • 市場規模の予測
  • 市場の魅力分析：流通チャネル別

第6章 世界の酵素補充療法市場の展望：地域別

  • 主なハイライト
  • 市場規模の推移
  • 市場規模の予測
    • 北米
    • 欧州
    • 東アジア
    • 南アジア・オセアニア
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析：地域

第7章 北米の酵素補充療法 (ERT) 市場の展望：推移・予測

  • 主なハイライト
  • 価格分析
  • 市場規模の推移
    • 国別
    • 対象疾患別
    • 投与経路別
    • 流通チャネル別
  • 市場規模の分析・予測：国別
    • 米国
    • カナダ
  • 市場規模の分析・予測：対象疾患別
    • ファブリー病
    • ゴーシェ病
    • ムコ多糖症（MPS）
    • ポンペ病
    • リソソーム酸性リパーゼ欠損症
    • その他
  • 市場規模の分析・予測：投与経路別
    • 経口酵素補充療法
    • 注射酵素補充療法
  • 市場規模の分析・予測：流通チャネル別
    • 病院薬局
    • 専門治療薬局
    • 小売薬局
  • 市場の魅力分析

第8章 欧州の酵素補充療法 (ERT) 市場の展望：推移・予測

  • 主なハイライト
  • 価格分析
  • 市場規模の推移
  • 市場規模の分析・予測：国別
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • トルコ
    • その他
  • 市場規模の分析・予測：対象疾患別
  • 市場規模の分析・予測：投与経路別
  • 市場規模の分析・予測：流通チャネル別
  • 市場の魅力分析

第9章 東アジアの酵素補充療法 (ERT) 市場の展望：推移・予測

  • 主なハイライト
  • 価格分析
  • 市場規模の推移
  • 市場規模の分析・予測：国別
    • 中国
    • 日本
    • 韓国
  • 市場規模の分析・予測：対象疾患別
  • 市場規模の分析・予測：投与経路別
  • 市場規模の分析・予測：流通チャネル別
  • 市場の魅力分析

第10章 南アジア・オセアニアの酵素補充療法 (ERT) 市場の展望：推移・予測

  • 主なハイライト
  • 価格分析
  • 市場規模の推移
  • 市場規模の分析・予測：国別
    • インド
    • 東南アジア
    • オーストラリア
    • その他
  • 市場規模の分析・予測：対象疾患別
  • 市場規模の分析・予測：投与経路別
  • 市場規模の分析・予測：流通チャネル別
  • 市場の魅力分析

第11章 ラテンアメリカの酵素補充療法 (ERT) 市場の展望：推移・予測

  • 主なハイライト
  • 価格分析
  • 市場規模の推移
  • 市場規模の分析・予測：国別
    • ブラジル
    • メキシコ
    • その他
  • 市場規模の分析・予測：対象疾患別
  • 市場規模の分析・予測：投与経路別
  • 市場規模の分析・予測：流通チャネル別
  • 市場の魅力分析

第12章 中東・アフリカの酵素補充療法 (ERT) 市場の展望：推移・予測

  • 主なハイライト
  • 価格分析
  • 市場規模の推移
  • 市場規模の分析・予測：国別
    • GCC諸国
    • エジプト
    • 南アフリカ
    • 北アフリカ
    • その他
  • 市場規模の分析・予測：対象疾患別
  • 市場規模の分析・予測：投与経路別
  • 市場規模の分析・予測：流通チャネル別
  • 市場の魅力分析

第13章 競合情勢

  • 市場シェア分析
  • 市場構造
  • 企業プロファイル (詳細：概要、財務、戦略、最近の動向)
    • Sanofi Genzyme
    • Shire (now part of Takeda Pharmaceuticals)
    • BioMarin Pharmaceutical Inc.
    • Amicus Therapeutics
    • Alexion Pharmaceuticals
    • Ultragenyx Pharmaceutical Inc.
    • Sarepta Therapeutics
    • Biomarin
    • Genzyme (now part of Sanofi)
    • Takeda Pharmaceuticals
    • Pfizer Inc.
    • AbbVie Inc.
    • Vertex Pharmaceuticals
    • Sangamo Therapeutics
    • Regeneron Pharmaceuticals Inc.
    • Spark Therapeutics (now part of Roche)
    • Orchard Therapeutics
    • Novartis AG
    • CSL Behring
    • Audentes Therapeutics

第14章 付録

目次
Product Code: PMRREP34935

Persistence Market Research presents an in-depth analysis of the Enzyme Replacement Therapy (ERT) Market, offering insights into its intricate dynamics and future trajectory. From market trends to growth catalysts, impediments, and emerging patterns, this report furnishes invaluable statistics and projections spanning from 2024 to 2031.

Key Insights:

  • Enzyme Replacement Therapy Market Size (2024): USD 11 Bn
  • Projected Market Value (2031): USD 17.7 Bn
  • Global Market Growth Rate (CAGR 2024 to 2031): 7.1%

Enzyme Replacement Therapy Market - Report Scope:

The Enzyme Replacement Therapy (ERT) Market encompasses various applications across healthcare sectors such as genetic disorders, lysosomal storage diseases, and metabolic disorders. This therapy involves the replacement of deficient or absent enzymes with recombinant or synthetic alternatives, significantly improving patients' quality of life. The market caters to a wide range of end-users, including pharmaceutical companies, healthcare providers, and specialized treatment centers, offering solutions for managing chronic conditions. Market growth is driven by factors such as rising prevalence of rare diseases, increasing healthcare expenditure, and advancements in biotechnology.

Market Growth Drivers:

The global Enzyme Replacement Therapy (ERT) Market is driven by key factors, including the rising prevalence of rare genetic disorders like Gaucher's disease, Fabry disease, and Pompe disease, spurred by improved diagnosis rates that boost therapy demand. Advancements in biotechnology, particularly in recombinant DNA technology, have enabled the development of highly effective and targeted treatments. Additionally, government support through financial assistance and reimbursement policies has expanded therapy accessibility, while growing awareness fueled by educational campaigns and patient advocacy groups continues to enhance diagnosis rates and treatment adoption.

Market Restraints:

While the Enzyme Replacement Therapy (ERT) Market demonstrates significant potential, it faces notable challenges. High treatment costs, including expenses related to research, manufacturing, and distribution, limit accessibility in low- and middle-income regions. Additionally, the complex manufacturing processes required for biologically active enzymes demand stringent regulatory compliance, often slowing down commercialization. Furthermore, adverse immune reactions in some patients necessitate careful monitoring and adjustments, which can hinder broader market adoption.

Market Opportunities:

The Enzyme Replacement Therapy (ERT) Market is ripe with opportunities, propelled by advancements in research and strategic collaborations. Emerging markets like Asia-Pacific and Latin America offer significant growth potential, driven by increasing awareness and improving healthcare infrastructure. The rise of personalized medicine, facilitated by genomic research and biomarker analysis, is enabling tailored ERT solutions for enhanced efficacy. Strategic partnerships among pharmaceutical companies, research institutions, and advocacy groups are accelerating innovation and expanding the reach of enzyme therapies. Moreover, the development of oral enzyme formulations and gene therapies marks a transformative shift, potentially replacing traditional intravenous treatments.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the Enzyme Replacement Therapy Market globally?
  • How are technological advancements and innovative delivery systems shaping the evolution of enzyme therapies?
  • What are the challenges and opportunities facing market participants in the ERT segment?
  • Which therapeutic areas and geographic regions offer the highest growth potential for enzyme replacement therapy manufacturers?
  • What strategies are leading companies employing to differentiate their offerings and capture market share in the competitive landscape?

Competitive Intelligence and Business Strategy:

Leading players in the global Enzyme Replacement Therapy Market are prioritizing innovation, strategic partnerships, and market expansion to secure a competitive edge. Companies are investing heavily in research and development to improve the efficacy and safety of enzyme therapies. Collaboration with academic institutions and patient advocacy organizations facilitates access to cutting-edge research and fosters community support.

Additionally, manufacturers are focusing on patient-centric initiatives, such as affordability programs and educational campaigns, to increase awareness and adoption of enzyme replacement therapies. Emphasis on quality assurance, regulatory compliance, and post-marketing surveillance enhances trust and long-term relationships with healthcare providers and patients.

Key Companies Profiled:

  • Sanofi S.A.
  • Pfizer Inc.
  • Shire (a Takeda company)
  • Biomarin Pharmaceutical Inc.
  • Alexion Pharmaceuticals, Inc.
  • AbbVie Inc.
  • Amicus Therapeutics, Inc.
  • Roche Holding AG
  • CSL Behring
  • Horizon Therapeutics Plc
  • Genzyme Corporation

Enzyme Replacement Therapy Market Research Segmentation:

By Therapeutic Area:

  • Lysosomal Storage Disorders
  • Gaucher Disease
  • Fabry Disease
  • Pompe Disease
  • Mucopolysaccharidosis
  • Metabolic Disorders
  • Others

By Route of Administration:

  • Intravenous
  • Oral
  • Others

By End-User:

  • Hospitals
  • Specialty Clinics
  • Research Institutes

By Region

North America

Latin America

Europe

South Asia and Oceania

East Asia

Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Enzyme Replacement Therapy Market Snapshot, 2024 and 2031
  • 1.2. Market Opportunity Assessment, 2024 - 2031, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
    • 2.3.3. Global Healthcare Spending Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Therapeutic Conditions Adoption Analysis
  • 3.2. Technology Assessment
  • 3.3. Regulatory Landscape
  • 3.4. Value Chain Analysis
  • 3.5. Key Deals and Mergers
  • 3.6. PESTLE Analysis
  • 3.7. Porter's Five Force Analysis

4. Price Trend Analysis, 2019 - 2031

  • 4.1. Key Highlights
  • 4.2. Key Factors Impacting Product Prices
  • 4.3. Pricing Analysis, By Therapeutic Conditions
  • 4.4. Regional Prices and Product Preferences

5. Global Enzyme Replacement Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 5.1. Key Highlights
    • 5.1.1. Market Volume (Units) Projections
    • 5.1.2. Market Size (US$ Bn) and Volume (Units) and Y-o-Y Growth
    • 5.1.3. Absolute $ Opportunity
  • 5.2. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast
    • 5.2.1. Historical Market Size (US$ Bn) and Volume (Units) Analysis, 2019 - 2023
    • 5.2.2. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, 2023-2031
  • 5.3. Global Enzyme Replacement Therapy Market Outlook: Therapeutic Conditions
    • 5.3.1. Introduction / Key Findings
    • 5.3.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Therapeutic Conditions, 2019 - 2023
    • 5.3.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapeutic Conditions, 2024 - 2031
      • 5.3.3.1. Fabry Disease
      • 5.3.3.2. Gaucher Disease
      • 5.3.3.3. Mucopolysaccharidosis (MPS)
        • 5.3.3.3.1. MPS I (Hurler Syndrome)
        • 5.3.3.3.2. MPS II (Hunter Syndrome)
        • 5.3.3.3.3. MPS IVA (Morquio Syndrome, Type A)
        • 5.3.3.3.4. MPS VI (Maroteaux-Lamy Syndrome)
        • 5.3.3.3.5. MPS VII (Sly Syndrome)
      • 5.3.3.4. Pompe Disease
      • 5.3.3.5. Lysosomal Acid Lipase Deficiency
      • 5.3.3.6. Others
  • 5.4. Market Attractiveness Analysis: Therapeutic Conditions
  • 5.5. Global Enzyme Replacement Therapy Market Outlook: Route of Administration
    • 5.5.1. Introduction / Key Findings
    • 5.5.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Route of Administration, 2019 - 2023
    • 5.5.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Route of Administration, 2024 - 2031
      • 5.5.3.1. Oral
      • 5.5.3.2. Injectable
  • 5.6. Market Attractiveness Analysis: Route of Administration
  • 5.7. Global Enzyme Replacement Therapy Market Outlook: Distribution Channel
    • 5.7.1. Introduction / Key Findings
    • 5.7.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Distribution Channel, 2019 - 2023
    • 5.7.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Distribution Channel, 2024 - 2031
      • 5.7.3.1. Hospital Pharmacies
      • 5.7.3.2. Specialty Treatment Pharmacies
      • 5.7.3.3. Retail Pharmacies
  • 5.8. Market Attractiveness Analysis: Distribution Channel

6. Global Enzyme Replacement Therapy Market Outlook: Region

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Region, 2019 - 2023
  • 6.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Region, 2024 - 2031
    • 6.3.1. North America
    • 6.3.2. Europe
    • 6.3.3. East Asia
    • 6.3.4. South Asia and Oceania
    • 6.3.5. Latin America
    • 6.3.6. Middle East & Africa
  • 6.4. Market Attractiveness Analysis: Region

7. North America Enzyme Replacement Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 7.1. Key Highlights
  • 7.2. Pricing Analysis
  • 7.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019 - 2023
    • 7.3.1. By Country
    • 7.3.2. By Therapeutic Conditions
    • 7.3.3. By Route of Administration
    • 7.3.4. By Distribution Channel
  • 7.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Country, 2024 - 2031
    • 7.4.1. U.S.
    • 7.4.2. Canada
  • 7.5. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapeutic Conditions, 2024 - 2031
    • 7.5.1. Enzyme Replacement Therapy for Fabry Disease
    • 7.5.2. Enzyme Replacement Therapy for Gaucher Disease
    • 7.5.3. Enzyme Replacement Therapy for Mucopolysaccharidosis (MPS)
    • 7.5.4. Enzyme Replacement Therapy for Pompe Disease
    • 7.5.5. Enzyme Replacement Therapy for Lysosomal Acid Lipase Deficiency
    • 7.5.6. Others
  • 7.6. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Route of Administration, 2024 - 2031
    • 7.6.1. Oral Enzyme Replacement Therapy
    • 7.6.2. Injectable Enzyme Replacement Therapy
  • 7.7. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Distribution Channel, 2024 - 2031
    • 7.7.1. Hospital Pharmacies
    • 7.7.2. Specialty Treatment Pharmacies
    • 7.7.3. Retail Pharmacies
  • 7.8. Market Attractiveness Analysis

8. Europe Enzyme Replacement Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 8.1. Key Highlights
  • 8.2. Pricing Analysis
  • 8.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019 - 2023
    • 8.3.1. By Country
    • 8.3.2. By Therapeutic Conditions
    • 8.3.3. By Route of Administration
    • 8.3.4. By Distribution Channel
  • 8.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Country, 2024 - 2031
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. U.K.
    • 8.4.4. Italy
    • 8.4.5. Spain
    • 8.4.6. Russia
    • 8.4.7. Turkey
    • 8.4.8. Rest of Europe
  • 8.5. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapeutic Conditions, 2024 - 2031
    • 8.5.1. Enzyme Replacement Therapy for Fabry Disease
    • 8.5.2. Enzyme Replacement Therapy for Gaucher Disease
    • 8.5.3. Enzyme Replacement Therapy for Mucopolysaccharidosis (MPS)
    • 8.5.4. Enzyme Replacement Therapy for Pompe Disease
    • 8.5.5. Enzyme Replacement Therapy for Lysosomal Acid Lipase Deficiency
    • 8.5.6. Others
  • 8.6. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Route of Administration, 2024 - 2031
    • 8.6.1. Oral Enzyme Replacement Therapy
    • 8.6.2. Injectable Enzyme Replacement Therapy
  • 8.7. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Distribution Channel, 2024 - 2031
    • 8.7.1. Hospital Pharmacies
    • 8.7.2. Specialty Treatment Pharmacies
    • 8.7.3. Retail Pharmacies
  • 8.8. Market Attractiveness Analysis

9. East Asia Enzyme Replacement Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 9.1. Key Highlights
  • 9.2. Pricing Analysis
  • 9.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019 - 2023
    • 9.3.1. By Country
    • 9.3.2. By Therapeutic Conditions
    • 9.3.3. By Route of Administration
    • 9.3.4. By Distribution Channel
  • 9.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Country, 2024 - 2031
    • 9.4.1. China
    • 9.4.2. Japan
    • 9.4.3. South Korea
  • 9.5. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapeutic Conditions, 2024 - 2031
    • 9.5.1. Enzyme Replacement Therapy for Fabry Disease
    • 9.5.2. Enzyme Replacement Therapy for Gaucher Disease
    • 9.5.3. Enzyme Replacement Therapy for Mucopolysaccharidosis (MPS)
    • 9.5.4. Enzyme Replacement Therapy for Pompe Disease
    • 9.5.5. Enzyme Replacement Therapy for Lysosomal Acid Lipase Deficiency
    • 9.5.6. Others
  • 9.6. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Route of Administration, 2024 - 2031
    • 9.6.1. Oral Enzyme Replacement Therapy
    • 9.6.2. Injectable Enzyme Replacement Therapy
  • 9.7. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Distribution Channel, 2024 - 2031
    • 9.7.1. Hospital Pharmacies
    • 9.7.2. Specialty Treatment Pharmacies
    • 9.7.3. Retail Pharmacies
  • 9.8. Market Attractiveness Analysis

10. South Asia & Oceania Enzyme Replacement Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 10.1. Key Highlights
  • 10.2. Pricing Analysis
  • 10.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019 - 2023
    • 10.3.1. By Country
    • 10.3.2. By Therapeutic Conditions
    • 10.3.3. By Route of Administration
    • 10.3.4. By Distribution Channel
  • 10.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Country, 2024 - 2031
    • 10.4.1. India
    • 10.4.2. Southeast Asia
    • 10.4.3. ANZ
    • 10.4.4. Rest of South Asia & Oceania
  • 10.5. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapeutic Conditions, 2024 - 2031
    • 10.5.1. Enzyme Replacement Therapy for Fabry Disease
    • 10.5.2. Enzyme Replacement Therapy for Gaucher Disease
    • 10.5.3. Enzyme Replacement Therapy for Mucopolysaccharidosis (MPS)
    • 10.5.4. Enzyme Replacement Therapy for Pompe Disease
    • 10.5.5. Enzyme Replacement Therapy for Lysosomal Acid Lipase Deficiency
    • 10.5.6. Others
  • 10.6. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Route of Administration, 2024 - 2031
    • 10.6.1. Oral Enzyme Replacement Therapy
    • 10.6.2. Injectable Enzyme Replacement Therapy
  • 10.7. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Distribution Channel, 2024 - 2031
    • 10.7.1. Hospital Pharmacies
    • 10.7.2. Specialty Treatment Pharmacies
    • 10.7.3. Retail Pharmacies
  • 10.8. Market Attractiveness Analysis

11. Latin America Enzyme Replacement Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 11.1. Key Highlights
  • 11.2. Pricing Analysis
  • 11.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019 - 2023
    • 11.3.1. By Country
    • 11.3.2. By Therapeutic Conditions
    • 11.3.3. By Route of Administration
    • 11.3.4. By Distribution Channel
  • 11.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Country, 2024 - 2031
    • 11.4.1. Brazil
    • 11.4.2. Mexico
    • 11.4.3. Rest of Latin America
  • 11.5. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapeutic Conditions, 2024 - 2031
    • 11.5.1. Enzyme Replacement Therapy for Fabry Disease
    • 11.5.2. Enzyme Replacement Therapy for Gaucher Disease
    • 11.5.3. Enzyme Replacement Therapy for Mucopolysaccharidosis (MPS)
    • 11.5.4. Enzyme Replacement Therapy for Pompe Disease
    • 11.5.5. Enzyme Replacement Therapy for Lysosomal Acid Lipase Deficiency
    • 11.5.6. Others
  • 11.6. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Route of Administration, 2024 - 2031
    • 11.6.1. Oral Enzyme Replacement Therapy
    • 11.6.2. Injectable Enzyme Replacement Therapy
  • 11.7. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Distribution Channel, 2024 - 2031
    • 11.7.1. Hospital Pharmacies
    • 11.7.2. Specialty Treatment Pharmacies
    • 11.7.3. Retail Pharmacies
  • 11.8. Market Attractiveness Analysis

12. Middle East & Africa Enzyme Replacement Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 12.1. Key Highlights
  • 12.2. Pricing Analysis
  • 12.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019 - 2023
    • 12.3.1. By Country
    • 12.3.2. By Therapeutic Conditions
    • 12.3.3. By Route of Administration
    • 12.3.4. By Distribution Channel
  • 12.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Country, 2024 - 2031
    • 12.4.1. GCC Countries
    • 12.4.2. Egypt
    • 12.4.3. South Africa
    • 12.4.4. Northern Africa
    • 12.4.5. Rest of Middle East & Africa
  • 12.5. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapeutic Conditions, 2024 - 2031
    • 12.5.1. Enzyme Replacement Therapy for Fabry Disease
    • 12.5.2. Enzyme Replacement Therapy for Gaucher Disease
    • 12.5.3. Enzyme Replacement Therapy for Mucopolysaccharidosis (MPS)
    • 12.5.4. Enzyme Replacement Therapy for Pompe Disease
    • 12.5.5. Enzyme Replacement Therapy for Lysosomal Acid Lipase Deficiency
    • 12.5.6. Others
  • 12.6. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Route of Administration, 2024 - 2031
    • 12.6.1. Oral Enzyme Replacement Therapy
    • 12.6.2. Injectable Enzyme Replacement Therapy
  • 12.7. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Distribution Channel, 2024 - 2031
    • 12.7.1. Hospital Pharmacies
    • 12.7.2. Specialty Treatment Pharmacies
    • 12.7.3. Retail Pharmacies
  • 12.8. Market Attractiveness Analysis

13. Competition Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. Market Structure
    • 13.2.1. Competition Intensity Mapping By Market
    • 13.2.2. Competition Dashboard
  • 13.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 13.3.1. Sanofi Genzyme
      • 13.3.1.1. Overview
      • 13.3.1.2. Segments and Therapeutic Conditions
      • 13.3.1.3. Key Financials
      • 13.3.1.4. Market Developments
      • 13.3.1.5. Market Strategy
    • 13.3.2. Shire (now part of Takeda Pharmaceuticals)
    • 13.3.3. BioMarin Pharmaceutical Inc.
    • 13.3.4. Amicus Therapeutics
    • 13.3.5. Alexion Pharmaceuticals
    • 13.3.6. Ultragenyx Pharmaceutical Inc.
    • 13.3.7. Sarepta Therapeutics
    • 13.3.8. Biomarin
    • 13.3.9. Genzyme (now part of Sanofi)
    • 13.3.10. Takeda Pharmaceuticals
    • 13.3.11. Pfizer Inc.
    • 13.3.12. AbbVie Inc.
    • 13.3.13. Vertex Pharmaceuticals
    • 13.3.14. Sangamo Therapeutics
    • 13.3.15. Regeneron Pharmaceuticals Inc.
    • 13.3.16. Spark Therapeutics (now part of Roche)
    • 13.3.17. Orchard Therapeutics
    • 13.3.18. Novartis AG
    • 13.3.19. CSL Behring
    • 13.3.20. Audentes Therapeutics

14. Appendix

  • 14.1. Research Methodology
  • 14.2. Research Assumptions
  • 14.3. Acronyms and Abbreviations